Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

DAPA-HF Investigators and Committees, Gislason, GH & Schou, M 2020, 'Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy', Diabetes Care, bind 43, nr. 11, s. 2878-2881. https://doi.org/10.2337/dc20-1402

APA

DAPA-HF Investigators and Committees, Gislason, G. H., & Schou, M. (2020). Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care, 43(11), 2878-2881. https://doi.org/10.2337/dc20-1402

CBE

DAPA-HF Investigators and Committees, Gislason GH, Schou M. 2020. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care. 43(11):2878-2881. https://doi.org/10.2337/dc20-1402

MLA

DAPA-HF Investigators and Committees, Gunnar Hilmar Gislason og Morten Schou. "Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy". Diabetes Care. 2020, 43(11). 2878-2881. https://doi.org/10.2337/dc20-1402

Vancouver

DAPA-HF Investigators and Committees, Gislason GH, Schou M. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care. 2020 nov;43(11):2878-2881. https://doi.org/10.2337/dc20-1402

Author

DAPA-HF Investigators and Committees ; Gislason, Gunnar Hilmar ; Schou, Morten. / Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. I: Diabetes Care. 2020 ; Bind 43, Nr. 11. s. 2878-2881.

Bibtex

@article{b990c6fca0bd43c6b6757716f675ccdd,
title = "Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy",
abstract = "OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.",
author = "Docherty, {Kieran F} and Jhund, {Pardeep S} and Olof Bengtsson and DeMets, {David L} and Inzucchi, {Silvio E} and Lars K{\o}ber and Kosiborod, {Mikhail N} and Langkilde, {Anna Maria} and Martinez, {Felipe A} and Sabatine, {Marc S} and Mikaela Sj{\"o}strand and Solomon, {Scott D} and McMurray, {John J V} and {DAPA-HF Investigators and Committees} and Gislason, {Gunnar Hilmar} and Morten Schou",
note = "{\textcopyright} 2020 by the American Diabetes Association.",
year = "2020",
month = nov,
doi = "10.2337/dc20-1402",
language = "English",
volume = "43",
pages = "2878--2881",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association",
number = "11",

}

RIS

TY - JOUR

T1 - Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

AU - Docherty, Kieran F

AU - Jhund, Pardeep S

AU - Bengtsson, Olof

AU - DeMets, David L

AU - Inzucchi, Silvio E

AU - Køber, Lars

AU - Kosiborod, Mikhail N

AU - Langkilde, Anna Maria

AU - Martinez, Felipe A

AU - Sabatine, Marc S

AU - Sjöstrand, Mikaela

AU - Solomon, Scott D

AU - McMurray, John J V

AU - DAPA-HF Investigators and Committees

A2 - Gislason, Gunnar Hilmar

A2 - Schou, Morten

N1 - © 2020 by the American Diabetes Association.

PY - 2020/11

Y1 - 2020/11

N2 - OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.

AB - OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.

U2 - 10.2337/dc20-1402

DO - 10.2337/dc20-1402

M3 - Journal article

C2 - 33082245

VL - 43

SP - 2878

EP - 2881

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -

ID: 61265145